TechCrunch Industry News China’s brain-computer interface industry is racing ahead
Feb 23, 2026
China’s brain-computer interface scene is shifting from lab research to commercial products. Policy roadmaps, big government funds, and massive clinical trial pools are accelerating progress. Manufacturing muscle and rising private investment are fueling startups and funding rounds. Innovations span invasive implants, non‑invasive systems, hybrid modalities, and efforts to improve implant longevity and regulation.
AI Snips
Chapters
Transcript
Episode notes
China Is Scaling BCIs Toward Commercial Healthcare
- China is rapidly moving BCIs from research to commercialization driven by policy, clinical trials, and investor interest.
- Provinces set medical pricing and national insurance inclusion, and Peng predicts multi-billion dollar healthcare market in 3–5 years.
Founder Phoenix Peng Runs Two BCI Startups
- Phoenix Peng founded two BCI startups: implantable NeuroXS and non-invasive Gestala, showing founder-led momentum.
- He envisions BCI as a bridge between neuroscience and AI, moving from medical use to eventual augmentation.
Four Structural Advantages Powering China’s BCI Lead
- Four drivers speed China's BCI progress: policy alignment, clinical resources, manufacturing, and strategic investment.
- National health insurance and quicker reimbursement shorten commercialization timelines compared with the U.S.